Home Cart Sign in  
Chemical Structure| 1014691-61-2 Chemical Structure| 1014691-61-2

Structure of GSK0660
CAS No.: 1014691-61-2

Chemical Structure| 1014691-61-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK0660 is a selective antagonist of PPARβ/δ and exhibits inverse agonist effects when used alone.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK0660

CAS No. :1014691-61-2
Formula : C19H18N2O5S2
M.W : 418.49
SMILES Code : O=C(C1=C(S(=O)(NC2=CC=C(NC3=CC=CC=C3)C=C2OC)=O)C=CS1)OC
MDL No. :MFCD12828770
InChI Key :NDFKBGWLUHKMFY-UHFFFAOYSA-N
Pubchem ID :46233311

Safety of GSK0660

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BAECs 2 µM 1 hour GSK0660 blocked the GW501516-mediated restoration of DHFR expression suppressed by PA Br J Pharmacol. 2019 Aug;176(16):2945-2961.
HUVECs 2 µM 1 hour GSK0660 significantly attenuated the GW501516-induced increase in DHFR expression Br J Pharmacol. 2019 Aug;176(16):2945-2961.
Bovine aortic endothelial cells (BAECs) 2 µM 1 hour GSK0660 blocked the GW501516-mediated alleviation of PA-induced DHFR expression reduction, further confirming the critical role of PPARδ in regulating DHFR expression. Br J Pharmacol. 2019 Aug;176(16):2945-2961.
Human umbilical vein endothelial cells (HUVECs) 2 µM 1 hour GSK0660, as a PPARδ antagonist, blocked the GW501516-induced increase in DHFR expression, demonstrating the regulatory role of PPARδ activation on DHFR expression. Br J Pharmacol. 2019 Aug;176(16):2945-2961.
Bovine aortic endothelial cells (BAECs) 1 µM 1 hour GSK0660 blocked the PCB2-induced activation of PPAR δ-driven gene transactivation. Redox Biol. 2020 Oct;37:101728.
Human umbilical vein endothelial cells (HUVECs) 1 µM 1 hour GSK0660, a selective PPAR δ antagonist, blocked the activation of PPAR δ by PCB2, thereby inhibiting the alleviating effect of PCB2 on high glucose-induced ER stress. Redox Biol. 2020 Oct;37:101728.
MC3T3-E1 cells 0.5 µM 1 hour GSK0660 inhibited bezafibrate-induced AMPK and eNOS phosphorylation, reducing them by 34.86% and 48.18% respectively. Acta Pharmacol Sin. 2011 May;32(5):591-600.
HUVECs 1 µM 1 hour Inhibited the protective effects of PPAR β agonists (GW0742 or L165041) on high glucose-induced impairment of insulin signaling Br J Pharmacol. 2014 Jun;171(12):3089-102.
Human retinal microvascular endothelial cells (HRMECs) 0.01, 0.1, 1.0 µM 12 hours GSK0660 inhibited VEGF-induced tube formation by 50.6% at the 1.0 μM concentration Invest Ophthalmol Vis Sci. 2013 Jun 19;54(6):4197-207.
INS-1E cells 1 µM 24 hours GSK0660 blocked the amplifying effect of high glucose preexposure on insulin secretion Diabetes. 2011 Nov;60(11):2830-42.
Human retinal microvascular endothelial cells (HRMECs) 10 µM 24 hours GSK0660 completely reversed VEGF-induced decreases in TEER of HRMEC monolayers, stabilized tight-junctions, reduced phosphorylation of Erk1/2, and decreased VEGFR1/2 expression. Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8232-40.
Human retinal microvascular endothelial cells (HRMECs) 0.01, 0.1, 1.0 µM 24 hours GSK0660 significantly reduced serum-induced HRMEC tube formation in a dose-dependent manner Invest Ophthalmol Vis Sci. 2013 Jun 19;54(6):4197-207.
Human retinal microvascular endothelial cells (HRMECs) 0.01, 0.1, 1.0 µM 24 hours GSK0660 significantly reduced serum-induced HRMEC proliferation in a dose-dependent manner Invest Ophthalmol Vis Sci. 2013 Jun 19;54(6):4197-207.
Human bronchial fibroblasts (HBFs) 10 µM 4 days To evaluate the effect of GSK0660 on TGF-β1-induced myofibroblast transition in HBFs. Results showed that GSK0660 alone had a slight inhibitory effect on the FMT potential of TGF-β1-stimulated HBFs. Int J Mol Sci. 2023 Apr 23;24(9):7721.
Human bronchial fibroblasts (HBFs) 10 µM 4 days To evaluate the effect of GSK0660 on the proliferation and viability of HBFs. Results showed that GSK0660 had no significant effect on the proliferation and viability of HBFs at concentrations up to 10 µM. Int J Mol Sci. 2023 Apr 23;24(9):7721.
Bovine aortic endothelial cells 1 µM 48 hours GSK0660 effectively prevented high-glucose-induced downregulation of glucose uptake Diabetes. 2010 Apr;59(4):808-18.
Rat aortic endothelial cells (RAECs) 5 µM 48 hours To evaluate the involvement of PPARδ in the protective effects of cinnamic acid (CA), GSK0660 inhibited the protective effects of CA against high glucose (HG)-induced endothelial dysfunction Chin Med. 2025 Jan 24;20(1):13.
Human retinal microvascular endothelial cells (HRMECs) 0.01, 0.1, 1.0 µM 6 hours GSK0660 significantly decreased angptl4 mRNA expression in a dose-responsive fashion Invest Ophthalmol Vis Sci. 2013 Jun 19;54(6):4197-207.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Spinal cord injury model Intraperitoneal injection 1 mg/kg 30 minutes before PEA administration GSK0660, as a PPAR-δ antagonist, reversed the protective effects of PEA on spinal cord injury J Neuroinflammation. 2013 Feb 1;10:20
Sprague-Dawley rats Streptozotocin-induced type-1 diabetic rat model Intravenous injection 1 mg/kg Once daily for 28 days GSK0660 was used to block PPARδ, reversing the effects of Rh2 on cardiac fibrosis and cardiac function improvement in diabetic rats. Int J Mol Sci. 2017 Jun 26;18(7):1364
Wistar rats Chronic central leptin infusion model Intraperitoneal injection 1 mg/kg/day Once daily for 7 days GSK0660 abolished the anorectic effects induced by icv leptin leading to increased visceral fat mass and reduced browning capacity. In addition, the pharmacological inhibition of PPAR β/δ alters the immunomodulatory actions of central leptin on eWAT. Int J Mol Sci. 2021 Apr 28;22(9):4624
C57BL/6J mice High glucose-induced endothelial dysfunction model Ex vivo aortic ring culture 1 μM Pretreated for 1 hour, then co-incubated with PCB2 and high glucose for 36 hours GSK0660 abolished the protective effect of PCB2 on high glucose-induced endothelial dysfunction, indicating that the effect of PCB2 depends on PPAR δ activation. Redox Biol. 2020 Oct;37:101728.
C57BL/6 mice VEGF-induced retinal vascular permeability model Intravitreal injection 10 μM Single injection, assessed after 24 hours GSK0660 significantly inhibited VEGF-induced retinal vascular permeability and reduced retinal VEGFR1 and VEGFR2 levels. Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8232-40.
Sprague-Dawley rats Oxygen-induced retinopathy (OIR) model Intravitreal injection; intraperitoneal injection 20, 100, 500 nM (intravitreal injection); 0.2, 1.0 mg/kg (intraperitoneal injection) Intravitreal injection on days 14(0) and 14(3); intraperitoneal injection on days 14(0), 14(2), and 14(4) GSK0660 significantly reduced retinal NV Invest Ophthalmol Vis Sci. 2013 Jun 19;54(6):4197-207.
Rat Diabetic mother offspring model In vitro culture 500 nM 16 hours GSK0660, as a PPARδ antagonist, was used to block the effects of the AMPK agonist A769662. The results showed that GSK0660 could inhibit the improvement of ER stress and endothelial dysfunction by A769662. Cardiovasc Res. 2022 Jul 27;118(10):2304-2316

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.95mL

2.39mL

1.19mL

23.90mL

4.78mL

2.39mL

References

 

Historical Records

Categories